Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
Immo Pharma Pas from Kasterlee, company number BE0443688490, closed financial year 2025 with a result of € -13,002 after tax. For that financial year Immo Pharma Pas recorded a gross margin of € 903 and equity of € 242,141. Compared with financial year 2024, the result moved from € -4,415 to € -13,002. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 6, 2025.
€ 242,141
▼ 5% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -13,002
▼ 195 % more loss than in 2024
Profit after tax over the fiscal year.
€ 187,335
▼ 11% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 180,141.
People and assets in 2025
€ 23,720
▼ 34% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 26
▼ 85% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 788
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 20,987 | € 25,613 | € 19,459 | € 903 | ▼ 95% |
| Profit after taxes | € 12,541 | € 6,942 | € -4,415 | € -13,002 | ▼ € 8,587 |
| Equity | € 317,661 | € 287,353 | € 255,143 | € 242,141 | ▼ 5% |
| Total debts | € 31,609 | € 27,074 | € 26,582 | € 833 | ▼ 97% |
| Cash | € 258,378 | € 231,060 | € 209,674 | € 187,335 | ▼ 11% |
| Retained profit | € 218,411 | € 225,353 | € 193,143 | € 180,141 | ▼ 7% |
| Dividend | € 0 | € 0 | € 27,795 | € 0 | ▼ 100% |
| Bank debt | € 3,372 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 349,270 | € 314,426 | € 281,725 | € 242,974 | ▼ 14% |
Key figures of Immo Pharma Pas, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to Immo Pharma Pas?
What happened at Immo Pharma Pas in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 13,002. Source: NBB ↗
- New establishment in Kasterlee. KBO
- Marleen Bellens became a director. NBB
- Willy Van Der Staey became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 12,541 profit in 2022 to € 13,002 loss in 2025.
Paid € 17,207 in corporate taxes since 2022.
Best year ever: 2022, with € 12,541 profit.
Paid out € 27,795 in dividends to the owners in total.
Management
Behind Immo Pharma Pas are Marleen Bellens and Willy Van Der Staey.
Directors
According to the 2025 annual accounts
Marleen Bellens
Director
since 1991
Willy Van Der Staey
Director
since 1991
Establishments
Establishment units
Physical locations of this company
Mezenstraat 2
2460 Kasterlee
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0443.688.490
- VAT number
- BE 0443.688.490
- Registered office
- Mezenstraat 2, 2460 Kasterlee
- Names & denominations
- Immo Pharma Pas
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 March 1991
- Peppol
- Active · Active since 4 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering